Quick Answer
LENZ Therapeutics, Inc. reported Net Income of -$82.13 million for fiscal year 2025.
LENZ Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$82.13M | -65.0% |
| 2024 | -$49.77M | +28.9% |
| 2023 | -$69.97M | +30.8% |
| 2022 | -$101.05M | -42.8% |
| 2021 | -$70.76M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$16.70M | -63.5% | -12.0% |
| June 30, 2025 | -$14.91M | -45.4% | -2.0% |
| March 31, 2025 | -$14.62M | +12.2% | -43.1% |
| September 30, 2024 | -$10.21M | +45.9% | +0.4% |
| June 30, 2024 | -$10.25M | +30.4% | +38.4% |
| March 31, 2024 | -$16.65M | -31.4% | +11.8% |
| September 30, 2023 | -$18.88M | +23.5% | -28.2% |
| June 30, 2023 | -$14.73M | +43.2% | -16.2% |
- LENZ Therapeutics, Inc. showed a decrease of -65.0% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, LENZ Therapeutics, Inc.’s net income has declined by 16.1% (from -$70.76 million to -$82.13 million).
- The most recent figure is from LENZ Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: